Przejdź do zawartości
Merck
  • Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives.

Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives.

Bioorganic & medicinal chemistry (2004-02-26)
Kannan P Naicker, Shibo Jiang, Hong Lu, Jiahong Ni, Louise Boyer-Chatenet, Lai-Xi Wang, Asim K Debnath
ABSTRAKT

A structure-based design approach has been used to optimize a lead HIV-1 entry inhibitor targeted to the envelope glycoprotein gp41. The docking study on this lead compound revealed important structural requirements that need to be preserved as well as structural non-requirements that could be eliminated to substantially reduce the molecular size of the lead compound. Based on the results from docking study, a limited number of analogues were designed and synthesized. This approach yielded a new analogue (compound 4) that retained the anti-HIV-1 activity with reduced molecular size approaching towards more drug-like character.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
2-Methoxy-5-methylaniline, 99%